Details of the Drug
General Information of Drug (ID: DMQ350F)
Drug Name |
5-chloro-1H-indole-2,3-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
5-Chloroisatin; 17630-76-1; 5-chloroindoline-2,3-dione; 5-Chloro-1H-indole-2,3-dione; 5-chlorisatin; 1H-Indole-2,3-dione, 5-chloro-; 5-chloro-2,3-dihydro-1H-indole-2,3-dione; 5-CHLORO ISATIN; 5-chlor-2,3-dioxoindolin; NSC 135811; XHDJYQWGFIBCEP-UHFFFAOYSA-N; MFCD00014567; 5-chlor-1h-indol-2,3-dion; 2HQ; EINECS 241-614-0; NSC135811; PubChem13607; ACMC-209zyf; 5-Chloroisatin, 97%; AC1Q3MRO; AC1Q3KL6; Isatin-based compound, 33; AC1Q3KL5; AC1L3D5R; 5-chloro-2,3-dioxoindolin; 5-Chloroindolin-2,3-dione; 1H-Indole-2, 5-chloro-; KSC174O1F
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 181.57 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||